• about us | Enterprise Therapeutics | Treatment of respiratory diseases

About Us

Enterprise Therapeutics

Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases. The company is backed by top tier venture capital investors and is based in the UK with offices at the University of Sussex Innovation Centre.

In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. Enterprise Therapeutics’ scientific strategy is aimed at discovering new disease modifying therapies that target the underlying mechanisms of mucus congestion, which will reduce the frequency of lung infections and improve patient quality of life.

These novel muco-regulatory therapies are being achieved through targeting TMEM16A and ENaC to increase the hydration and clearance of mucus. Enterprise has also identified novel targets and compounds that reduce mucus production, an approach that compliments mucus hydration therapies.

Its management team has significant expertise in drug discovery, drug development, respiratory biology and ion channel pharmacology. The company benefits from a close working relationship with the School of Life Sciences at the University of Sussex.

Meet the teams

Leadership Team

Impressive drug discovery and development team with extensive experience in delivering novel and effective treatments for respiratory diseases in pharma and biotech settings.

Learn more

Board

International blend of leading corporate (Novartis Venture Fund) and more traditional venture investors (Versant, Forbion, IP Group, Epidarex) bringing individuals with a fantastic track record in Pharma and building exceptional Biotech companies.

Learn more

Advisory Board

We work closely with leading scientific experts and world-renowned physicians involved in the development of new treatments for respiratory diseases.

Learn more

About Cystic Fibrosis (CF)

CF is the most common lethal genetic disease of Caucasians with an estimated 70,000 patients worldwide. The average life expectancy, although improving, is approximately 40 years.

About Chronic Obstructive Pulmonary Disease (COPD)

COPD is a chronic disease characterised by a progressive and irreversible decrease in lung function. Globally, COPD is reported to affect over 300 million people and in 2012 was the world’s third highest killer. The estimated economic cost of COPD is >$2 trillion.

About Severe Asthma

Patients with severe asthma are either refractory or poorly managed by current therapies (bronchodilators, steroids). Severe asthma patients comprise around 5% of the estimated 300 million global asthma patients.

Enterprise is a biopharmaceutical company dedicated to the research and development of novel therapies for the treatment of respiratory diseases of high unmet medical need and commercial opportunity – the company plans to initiate clinical trials in 2019.

Scientific Strategy

Enterprise is developing muco-regulatory drugs that are expected to help respiratory patients by improving their ability to breath and reduce the number of lung infections they experience leading to a longer and more healthy life.

Learn more

Pipeline

Enterprise has developed a pipeline of novel low molecular weight compounds with first in class potential – our most advanced compounds, which target ion channels in the airway epithelium are expected to enter human trials in late 2019.

Learn more